Autism Disorder Treatment Market Forecast from 2015 till 2025
Autism is known as autism spectrum disorder (ASD) scientifically. It is recognized by symptoms such as repetitive behavior, problems with non-verbal communication, and social skills. Such symptoms differ from patient to patient, therefore, called autism spectrum disorder. The symptom of autism can appear in the age of 2-3 years of an individual. The exact reason of disorder is not known. However, genes and environmental factors can be the cause of incidence of autism.
More Insightful Information | Request a Sample Copy @ https://www.reportsmonitor.com/request_sample/18343
According to National Institute of Neurological Disorders and Stroke, autism can appear in every ethnic and racial group. Whereas, boys are more prone to autism disorder than girls. Furthermore, according to the estimation of Centers for Disease Control and Prevention, almost 1 in 68 children are affected by ASD
National Library of Medicine stated that there is no treatment available for the autism disorder. Nevertheless, there are several therapies available including communication therapies and therapeutic medicines for the control of the disorder and child’s ability to learn new skills.
Global autism market is driven by factors such as awareness activities sponsored by government and increasing prevalence of the disorder. Moreover, new products innovation associated with advanced technology and rising number of pharmaceutical companies are anticipated to boost the growth of the market. Moreover, e-learning awareness programs across the world have created a positive impact on the market. Furthermore, several clinical trials are going on to develop new medications for ASD including RG7314 and AT001 (Fluoxetine rapid dissolve) etc.
Geographically, autism disorder treatment market can be segmented as North America, Europe, Asia Pacific, and LAMEA. North America is expected to be dominant in the market owing to several factors including increasing awareness associated with autism disorder, and rising patient population. According to the estimation of the Center for Disease Control & Prevention (CDC), the rate of diagnosis of ASD increased around 4.55% in 2016 as compared to 3.57% in 2014.
Europe is predicted to be growing market due to increasing investment in research and development associated with autism and the rising number of awareness programs emphasized on potential treatment available for the disorder such as Trans-European program. The Asia-pacific market is predicted to rise attributed to factors including the rising health-care infrastructure and number of global key players present in the region.
Latin America and Middle East & Africa are lacking in the autism disorder treatment market, owing to the inaccessibility of treatment and lack of awareness about alternative treatment available in the market. However, this region is expected to grow during the forecast period attributed to factors such as the rising investment by global key players in the region.
Prominent key players in the market are GlaxoSmithKline plc., Allergan, Eli Lilly and Company, Merck & CO Inc., Consern Pharma Private Limited, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb, Novartis International Ltd., and Pfizer Inc.
Get Discount of Autism Disorder Treatment Market Report: https://www.reportsmonitor.com/check_discount/18343
In March 2017, an international pharmaceutical company, Servier, signed an agreement with Neurochlore to develop a medicine for the prevention and cure of autism spectrum disorder. Neurochlore is a french company, specialized in developmental neurobiology. The company’s strategic partnership comprises of development of clinical three phase trials of an oral liquid medicine for affected children.
In December 2017, University of California, Los Angeles, has received approval from National Institutes of Health for identifying mechanism of molecular that causes the autism disorder. This project is worth more than $5 million. Similar approval was granted for understanding the causes of autism spectrum disorder. In Nov 2017, National Institute of Mental Health gave approval to School of Medicine and UCLA to study the facts associated with autism disorder and cellular processes that are responsible for ASD. This project is worth around $9.3 million.
In December 2017, Zelda Therapeutics Ltd of Australia entered into a partnership with Children’s Hospital of Philadelphia (CHOP) to study the potential treatment available for autism disorder.
Pervasive Developmental Disorder
By Type of Treatment
Auditory Integration Training
Hyperbaric Oxygen Therapy
Stimulants – Ritalin
North America (U.S and Canada)
Europe (Germany, France, Italy and Rest of Europe)
Asia-Pacific (China, Japan, India, South Korea and Rest of Asia-Pacific)
LAMEA (Brazil, Turkey, Saudi Arabia, South Africa and Rest of LAMEA)
Reports Monitor is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries including Healthcare, Technology, Chemicals, Materials, and Energy. With an intrinsic understanding of many business environments, Reports Monitor provides strategic objective insights.
We periodically update our market research studies to ensure our clients get the most recent, relevant, and valuable information. Reports Monitor has a strong base of analysts and consultants from assorted areas of expertise. Our industry experience and ability to zero-in on the crux of any challenge gives you and your organization the ability to secure a competitive advantage.
Direct: +1 513 549-5911 (U.S.)
+44 203 318 2846 (U.K.)
Company Name: Reports Monitor
Contact Person: Jay Matthews
Email: Send Email
Phone: +1 513 549-5911